Search results
Found 6999 matches for
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
The F1000 Research Group
Studying brain growth, health and development during the first 1000 days of life
HIV Research Group
Our group’s work is focused on the South African HIV epidemic. Although the group is based in Oxford, we have over the past 20 years developed strong collaborations in Durban and Kimberley, South Africa. Our group’s major focus is on HIV-infected children; specifically: (1) the impact of differences in the immune response in adults and children on HIV disease and HIV cure/remission potential in children; and (2) the impact of sex differences in the immune response, from conception through adolescence, on HIV disease and HIV cure/remission potential in children.
Developmental Immunology Research Group
This group is headed up by Professor G. Hollander who specialises in the molecular and cellular control of thymus development and function.
Oxford Vaccine Group
The Oxford Vaccine Group (OVG) conducts studies of new and improved vaccines for adults and children against diseases including meningococcus, pneumococcus, RSV, influenza, typhoid and paratyphoid. The group is based in the Department of Paediatrics in the University of Oxford at the Oxford Vaccine Centre, Churchill Hospital, and is led by Professor Andrew J. Pollard.
Specialised Translational Research Oxford Neuromuscular Group: STRONG
Our group aims to: conduct and design best clinical trials in neuromuscular diseases; accelerate clinical trial development through innovative outcome measures and newborn screening; understand progress of the disease and apply personalised care; connect with families and act as a strong reference point; assess effectiveness of current treatment therapies; minimise undiagnosed cases and time to targeted intervention.
Wood Group
Nucleic Acid Gene Therapy in Brain and Muscle
Early Prevention of Cardiometabolic Disease Group
The work of this group is focused on prevention of cardiometabolic disease in the young. More people die from such disease worldwide than from any other cause. The majority of these deaths are due to coronary heart disease (CHD) and stroke, potentially preventable conditions.
Mucosal Immunology
The gastrointestinal immune system has evolved to avoid and counteract the invasion of pathogens. To allow a strong inflammatory immune response during infection but avoid tissue damage there is a need for barrier function and effective immune regulation. Defects in immune regulation lead to immunopathology such as inflammatory bowel disease or celiac disease. We study mechanisms of intestinal barrier function as well as immune regulation by analysing patients with Mendelian disorders that develop intestinal inflammation.
Childhood Leukaemia Research Group
Founded in 2015, we are investigating the link between human fetal haematopoiesis and the origin and biology of childhood leukaemia. In particular, we are interested in the pathogenesis of infant leukaemia, which is a refractory disease that invariably originates in utero.
Fetal and Neonatal Haematology Group
We aim to discover the developmentally-regulated, molecular and biological properties of fetal haematopoietic stem and progenitor cells (HSPC) that provide the permissive cellular context for leukaemia and anemia in early childhood and to investigate the mechanisms which drive these changes.
Paediatric Neuroimaging
Our research focuses on human neonatal brain development. We undertake mechanistic research, clinical trials, methodology development (MRI, EEG and analytical approaches), with a particular focus on infant pain.